Lois B Travis
Overview
Explore the profile of Lois B Travis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
4682
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kerns S, Dinh Jr P, Monahan P, Stump T, Fung C, Sesso H, et al.
J Natl Cancer Inst
. 2025 Feb;
PMID: 39898813
Background: To comprehensively evaluate the longitudinal progression of cumulative burden of morbidity (CBM) in testicular cancer survivors (TCS) following standard-dose cisplatin-chemotherapy and the impact of modifiable risk factors on morbidity...
2.
Shahbazi M, Wheeler H, Armstrong G, Frisina R, Travis L, Dolan M
Sci Rep
. 2024 Nov;
14(1):27952.
PMID: 39543288
Tinnitus is a common sensorineural complication that can occur de novo or after cancer treatments involving cisplatin or radiotherapy. Considering the heterogeneous etiology and pathophysiology of tinnitus, the extent to...
3.
Dinh Jr P, Monahan P, Fung C, Sesso H, Feldman D, Vaughn D, et al.
JNCI Cancer Spectr
. 2024 Aug;
8(5).
PMID: 39141447
No study has comprehensively examined associated factors (adverse health outcomes, health behaviors, and demographics) affecting cognitive function in long-term testicular cancer survivors (TC survivors). TC survivors given cisplatin-based chemotherapy completed...
4.
Sanchez V, Dinh Jr P, Monahan P, Althouse S, Rooker J, Sesso H, et al.
JAMA Oncol
. 2024 Jun;
10(7):912-922.
PMID: 38842797
Importance: Cisplatin is highly ototoxic but widely used. Evidence is lacking regarding cisplatin-related hearing loss (CRHL) in adult-onset cancer survivors with comprehensive audiologic assessments (eg, Words-in-Noise [WIN] tests, full-spectrum audiometry,...
5.
Dinh Jr P, Monahan P, Fossa S, Sesso H, Feldman D, Dolan M, et al.
J Natl Cancer Inst
. 2023 Nov;
116(3):455-467.
PMID: 37966940
Background: No study has quantified the impact of pain and other adverse health outcomes on global physical and mental health in long-term US testicular cancer survivors or evaluated patient-reported functional...
6.
Travis L, Feldman D, Fung C, Poynter J, Lockley M, Frazier A
J Clin Oncol
. 2023 Oct;
42(6):696-706.
PMID: 37820296
Innovations in the care of adolescent and young adult (AYA) germ cell tumors (GCTs) are needed for one of the most common AYA cancers for which treatment has not significantly...
7.
Clasen S, Fung C, Sesso H, Travis L
Curr Oncol Rep
. 2023 Mar;
25(5):445-454.
PMID: 36867377
Purpose Of Review: Testicular cancer (TC) is the leading cancer in men between 18 and 39 years of age. Current treatment involves tumor resection followed by surveillance and/or one or...
8.
Sanchez V, Dinh Jr P, Rooker J, Monahan P, Althouse S, Fung C, et al.
J Cancer Surviv
. 2023 Jan;
17(1):27-39.
PMID: 36637632
Purpose: Ototoxicity is a prominent side effect of cisplatin-based chemotherapy. There are few reports, however, estimating its prevalence in well-defined cohorts and associated risk factors. Methods: Testicular cancer (TC) survivors...
9.
Sanchez V, Shuey M, Dinh Jr P, Monahan P, Fossa S, Sesso H, et al.
J Clin Oncol
. 2023 Jan;
41(12):2211-2226.
PMID: 36626694
Purpose: Cisplatin is widely used and highly ototoxic, but patient-reported functional impairment because of cisplatin-related hearing loss (HL) and tinnitus has not been comprehensively evaluated. Patients And Methods: Testicular cancer...
10.
Shahbazi M, Zhang X, Dinh P, Sanchez V, Trendowski M, Shuey M, et al.
Cancer Med
. 2022 Sep;
12(3):2999-3012.
PMID: 36097363
Purpose: Deficits in speech understanding constitute one of the most severe consequences of hearing loss. Here we investigate the clinical and genetic risk factors for symmetric deterioration of speech recognition...